{"id":9889,"date":"2026-07-27T22:29:13","date_gmt":"2026-07-28T03:29:13","guid":{"rendered":"https:\/\/fifarma.org\/?post_type=publicaciones&p=9889"},"modified":"2026-08-20T17:20:56","modified_gmt":"2026-08-20T22:20:56","slug":"fifarma-patient-wait-indicator-2026","status":"publish","type":"publicaciones","link":"https:\/\/fifarma.org\/pt\/publicaciones\/fifarma-patient-wait-indicator-2026\/","title":{"rendered":"FIFARMA Patient W.A.I.T. Indicator 2026 (ENG)"},"content":{"rendered":"

This report, developed by FIFARMA in collaboration with IQVIA, analyzes access to innovative medicines in Latin America and the main barriers influencing their availability. The study shows that, on average, patients wait 5.7 years from the global approval of an innovative therapy until it becomes available. Based on the analysis of 447 innovative molecules approved between 2014 and 2025 in ten countries across the region, the report identifies opportunities to improve access and strengthen health systems in the face of innovation.<\/p>\n\n\n\n

Read document<\/a><\/strong><\/p>","protected":false},"author":24,"parent":0,"template":"","ano":[187],"idioma":[45],"etiquetas-publicacion":[173,89],"categoria-publicacion":[29],"class_list":["post-9889","publicaciones","type-publicaciones","status-publish","hentry","ano-187","idioma-english","etiquetas-publicacion-wait","etiquetas-publicacion-wait-indicator","categoria-publicacion-reporte"],"yoast_head":"\nFIFARMA Patient W.A.I.T. Indicator 2026 (ENG)<\/title>\n<meta name=\"description\" content=\"FIFARMA W.A.I.T. Indicator 2026: Analysis of access to innovative medicines across 10 Latin American countries and 447 approved molecules.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/pt\/publicacoes\/fifarma-patient-wait-indicator-2026\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FIFARMA Patient W.A.I.T. Indicator 2026 (ENG)\" \/>\n<meta property=\"og:description\" content=\"FIFARMA W.A.I.T. Indicator 2026: Analysis of access to innovative medicines across 10 Latin American countries and 447 approved molecules.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/pt\/publicacoes\/fifarma-patient-wait-indicator-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-20T22:20:56+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-patient-wait-indicator-2026\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-patient-wait-indicator-2026\\\/\",\"name\":\"FIFARMA Patient W.A.I.T. Indicator 2026 (ENG)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"datePublished\":\"2026-07-28T03:29:13+00:00\",\"dateModified\":\"2026-08-20T22:20:56+00:00\",\"description\":\"FIFARMA W.A.I.T. Indicator 2026: Analysis of access to innovative medicines across 10 Latin American countries and 447 approved molecules.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-patient-wait-indicator-2026\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-patient-wait-indicator-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-patient-wait-indicator-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publicaciones\",\"item\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FIFARMA Patient W.A.I.T. Indicator 2026 (ENG)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FIFARMA Patient W.A.I.T. Indicator 2026 (ENG)","description":"FIFARMA W.A.I.T. Indicator 2026: Analysis of access to innovative medicines across 10 Latin American countries and 447 approved molecules.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/pt\/publicacoes\/fifarma-patient-wait-indicator-2026\/","og_locale":"pt_BR","og_type":"article","og_title":"FIFARMA Patient W.A.I.T. Indicator 2026 (ENG)","og_description":"FIFARMA W.A.I.T. Indicator 2026: Analysis of access to innovative medicines across 10 Latin American countries and 447 approved molecules.","og_url":"https:\/\/fifarma.org\/pt\/publicacoes\/fifarma-patient-wait-indicator-2026\/","og_site_name":"FIFARMA","article_modified_time":"2026-08-20T22:20:56+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-patient-wait-indicator-2026\/","url":"https:\/\/fifarma.org\/publicaciones\/fifarma-patient-wait-indicator-2026\/","name":"FIFARMA Patient W.A.I.T. Indicator 2026 (ENG)","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"datePublished":"2026-07-28T03:29:13+00:00","dateModified":"2026-08-20T22:20:56+00:00","description":"FIFARMA W.A.I.T. Indicator 2026: Analysis of access to innovative medicines across 10 Latin American countries and 447 approved molecules.","breadcrumb":{"@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-patient-wait-indicator-2026\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/publicaciones\/fifarma-patient-wait-indicator-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-patient-wait-indicator-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"Publicaciones","item":"https:\/\/fifarma.org\/publicaciones\/"},{"@type":"ListItem","position":3,"name":"FIFARMA Patient W.A.I.T. Indicator 2026 (ENG)"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Federa\u00e7\u00e3o Latino-Americana da Ind\u00fastria Farmac\u00eautica","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/publicaciones\/9889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/publicaciones"}],"about":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/types\/publicaciones"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/users\/24"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/media?parent=9889"}],"wp:term":[{"taxonomy":"ano","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/ano?post=9889"},{"taxonomy":"idioma","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/idioma?post=9889"},{"taxonomy":"etiquetas-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/etiquetas-publicacion?post=9889"},{"taxonomy":"categoria-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/pt\/wp-json\/wp\/v2\/categoria-publicacion?post=9889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}